** Shares of vaccine maker Novavax NVAX.O rise 13% to $7.06 premarket
** Co says its COVID-19 vaccine is "approvable based on conversations with the U.S. Food and Drug Administration (FDA)"
** NVAX also says it has received a request from the FDA for a commitment to provide additional clinical data on its vaccine if it secures an approval
** The FDA had missed its deadline for making a decision on traditional approval for co's protein-based shot earlier this month
** Up to last close, stock had fallen 22.3% YTD
(Reporting by Puyaan Singh)
((Puyaan.Singh@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。